A Mettl16/m6A/mybl2b/Igf2bp1 axis ensures cell cycle progression of embryonic hematopoietic stem and progenitor cells
Yunqiao Han,Kui Sun,Shanshan Yu,Yayun Qin,Zuxiao Zhang,Jiong Luo,Hualei Hu,Liyan Dai,Manman Cui,Chaolin Jiang,Fei Liu,Yuwen Huang,Pan Gao,Xiang Chen,Tianqing Xin,Xiang Ren,Xiaoyan Wu,Jieping Song,Qing Wang,Zhaohui Tang,Jianjun Chen,Haojian Zhang,Xianqin Zhang,Mugen Liu,Daji Luo
DOI: https://doi.org/10.1038/s44318-024-00082-9
2024-04-12
The EMBO Journal
Abstract:Prenatal lethality associated with mouse knockout of Mettl16, a recently identified RNA N6-methyladenosine (m 6 A) methyltransferase, has hampered characterization of the essential role of METTL16-mediated RNA m 6 A modification in early embryonic development. Here, using cross-species single-cell RNA sequencing analysis, we found that during early embryonic development, METTL16 is more highly expressed in vertebrate hematopoietic stem and progenitor cells (HSPCs) than other methyltransferases. In Mettl16-deficient zebrafish, proliferation capacity of embryonic HSPCs is compromised due to G1/S cell cycle arrest, an effect whose rescue requires Mettl16 with intact methyltransferase activity. We further identify the cell-cycle transcription factor mybl2b as a directly regulated by Mettl16-mediated m 6 A modification. Mettl16 deficiency resulted in the destabilization of mybl2b mRNA, likely due to lost binding by the m 6 A reader Igf2bp1 in vivo. Moreover, we found that the METTL16-m 6 A-MYBL2-IGF2BP1 axis controlling G1/S progression is conserved in humans. Collectively, our findings elucidate the critical function of METTL16-mediated m 6 A modification in HSPC cell cycle progression during early embryonic development.
cell biology,biochemistry & molecular biology